Drug Cos. Can't Nix Monitoring Class In Zantac MDL
A Florida federal judge won't let drugmakers escape claims from a class alleging that their use of Zantac and its generics have given them an increased risk of cancer, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article